Clinical Trial Update: Copanlisib and Gemcitabine in Relapsed/Refractory PTCL [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating copanlisib with gemcitabine in relapsed/refractory mature T-cell and NK-cell neoplasms has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mature T-cell and Nk-cell Neoplasm

Drugs mentioned

• Copanlisib (copanlisib)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Chonnam National University Hospital | Conditions: Mature T-Cell and NK-Cell Neoplasm | Phase 1, Phase 2 | Status: COMPLETED